Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders by Jones, Daniel P. & Patel, Jyoti
                          Jones, D. P., & Patel, J. (2018). Therapeutic Approaches Targeting
Inflammation in Cardiovascular Disorders. Biology, 7(4), [49].
https://doi.org/10.3390/biology7040049
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.3390/biology7040049
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via MDPI at
https://www.mdpi.com/2079-7737/7/4/49 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
biology
Review
Therapeutic Approaches Targeting Inflammation in
Cardiovascular Disorders
Daniel P. Jones 1 and Jyoti Patel 2,3,*
1 Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK;
bq18532@bristol.ac.uk
2 Division of Cardiovascular Medicine, Radcliffe Department of Medicine, British Heart Foundation Centre of
Research Excellence, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU, UK
3 Wellcome Trust Centre for Human Genetics, Radcliffe Department of Medicine, University of Oxford,
Oxford OX3 7BN, UK
* Correspondence: jyoti.patel@well.ox.ac.uk; Tel.: +44-186-528-662
Received: 23 October 2018; Accepted: 6 November 2018; Published: 16 November 2018


Abstract: Cardiovascular disease is a leading cause of morbidity and mortality in the Western world
and represents an enormous global health burden. Significant advances have been made in the
conservative, medical and surgical management across the range of cardiovascular diseases however
the inflammatory components of these diseases have traditionally been neglected. Inflammation
is certainly a key component of atherosclerosis, a chronic inflammatory condition, but it is at least
correlative and predictive of risk in many other aspects of cardiovascular medicine ranging from heart
failure to outcomes following reperfusion strategies. Inflammation therefore represents significant
potential for future risk stratification of patients as well as offering new therapeutic targets across
cardiovascular medicine. This review explores the role of inflammation in several of the major aspects
of cardiovascular medicine focusing on current and possible future examples of the targeting of
inflammation in prognosis and therapy. It concludes that future directions of cardiovascular research
and clinical practice should seek to identify cohorts of patients with a significant inflammatory
component to their cardiovascular condition or reaction to cardiovascular intervention. These
patients might benefit from therapeutic strategies mounted against the inflammatory components
implicated in their condition.
Keywords: inflammation; atherosclerosis; myocardial infarction; heart failure; randomised
controlled trial
1. Introduction
Cardiovascular medicine has been a notable success of the twentieth century with the development
of a variety of effective therapies [1]. In the case of atherosclerosis, for example, management has been
transformed by the discovery of a range of modifiable lifestyle factors and novel revascularisation
techniques such as coronary artery bypass grafting (CABG) and percutaneous coronary intervention
(PCI). However, it was only in the late 20th century that the inflammatory components of these diseases
began to be explored [2]. This soon led to the widespread acceptance of the Ross hypothesis [3], which
firmly establishes atherosclerosis as a chronic inflammatory disease as opposed to simply a disease of
lipid dysfunction.
Further to this, we now have a growing volume of experimental evidence that inflammation
has roles in heart failure, myocardial infarction (MI) and responses to cardiac interventions [4–6].
Inflammatory biomarkers have now been investigated for correlation and predictive capabilities in
many aspects of cardiovascular medicine [7,8] and there have been numerous anti-inflammatory
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strategies attempted in many of these conditions [9,10]. However, in clinical practice most of
these strategies have enjoyed little success with a few notable exceptions (see Tables 1–4). This
is due to a traditionally blunted approach incorporating non-specific inflammatory biomarkers and
anti-inflammatory therapies [11].
This review will explore the role of inflammation in the clinical management of atherosclerosis and
myocardial infarction; as well as that of heart failure which is a major consequence of these conditions.
It will also address the impact of inflammation in the reperfusion strategies used in these conditions,
namely CABG and PCI. Finally, it will suggest possible future directions in each of these topics. In
future, we envisage an approach that risk stratifies patients according to inflammatory biomarkers and
utilises new therapies specifically targeting inflammatory processes unique to cardiovascular disease.
2. Atherosclerosis
2.1. The use of Inflammatory Biomarkers in Atherosclerosis
Atherosclerosis is a chronic inflammatory condition affecting the medium- and large-sized
arteries, characterised by the progressive development of lesions consisting of lipid, fibrosis, and
inflammatory cell infiltrate within the tunica media [12]. The progression of these lesions into complex
atherosclerotic plaques is in turn associated with vessel stenosis and plaque rupture with the generation
of atheromatous thromboembolism [13]. It is the major pathological process underlying several
cardiovascular diseases, such as MI and stroke, and is thus a leading contributor to morbidity and
mortality [14].
Atherosclerosis has seen intense research activity targeting reductions in C-reactive protein (CRP)
as a result of retrospective analysis of primary prevention trials with statins which found that the
benefits of statins were not solely due to their reduction of low-density lipoprotein (LDL) [15,16].
Instead, part of the efficacy of statins has been attributed to the suggested anti-inflammatory properties
of statins. In most of these trials CRP was shown to predict future cardiovascular events and a CRP
level >2 mg/dL predicted a treatment response independent of LDL targets being achieved.
There is now a proposed ‘residual inflammation’ in certain individuals that accounts for
cardiovascular risk in the presence of normal or low LDL. Notably, the JUPITER trial (Justification
for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) specifically
demonstrated that at-risk individuals with elevated high-sensitivity CRP (hs-CRP) but normal
cholesterol can significantly reduce their risk of MI and stroke by taking statins [17]. More recently, it
has been established that the cardiovascular event hazard ratio of CRP is comparable to that of total
cholesterol. These results, in combination with widespread and cheap availability of CRP measurement
technology, have seen CRP reduction become the focus of several phase II trials investigating therapies
targeting inflammation in cardiovascular disease [8]. However, the use of CRP as a direct marker
of cardiovascular inflammation has proved controversial. In stable acute coronary syndrome (ACS)
patients for instance, CRP was shown to not be predictive of future cardiovascular events [18]. More
compellingly, in phase II trials incorporating imaging modalities of atherosclerotic lesions it has been
shown that CRP reduction does not correlate with changes in plaque size or composition [19].
Other pro-inflammatory substances have also been explored: IL-6 administration exacerbates
atherosclerosis in mice and it has been shown to be elevated in those with stable cardiovascular disease
and is an independent predictor of cardiovascular events [20]. Fibrinogen, an acute phase reactant
involved in thrombus formation, has also been investigated and shown to independently predict
cardiovascular events [21]. There has also been interest in monocyte phenotypes as an inflammatory
biomarker in atherosclerosis. In humans, there is a pro-inflammatory CD14++ CD16+ monocyte
population [22], this population appears to be an intermediate to the murine CX3CR1lo/Ly6Chi
monocyte population previously discussed [17]. It is expanded relative to the anti-inflammatory
population in coronary heart disease and its level correlates with plaque vulnerability as demonstrated
by coronary CT studies [23,24]. The level of this population has now been shown in several population
Biology 2018, 7, 49 3 of 14
studies to be an independent risk factor for future cardiovascular events [25,26]. Even in asymptomatic
patients, the level has been shown to be predictive of subclinical atherosclerosis [27].
2.2. The Use of Anti-Inflammatory Therapies in Atherosclerosis
The chronic nature of atherosclerosis coupled with the sheer proportion of the population
who have a subclinical form makes potent anti-inflammatory therapies with numerous side effects,
corticosteroids for example, undesirable. Therefore, the challenge has been to develop specific
immunosuppressive or immunomodulatory therapies with minimal side effects. Given the role of
oxidized LDL in promoting macrophage activation and inflammation within atherosclerotic lesions [15],
specific therapies have been developed to target it, either directly or through anti-oxidant action. The
phase III ARISE trial (Aggressive Reduction in Inflammation Stops Events) saw succinobucol, an
anti-oxidant and anti-inflammatory, used in the prevention of cardiovascular events following recent
ischaemia after promising phase II results. However, it failed to demonstrate efficacy during follow up
and instead produced significant elevations in LDL [28].
Phospholipase 2 (PLA2) inhibitors similarly reduce levels of oxidized LDL and so were speculated
to beneficial in atherosclerosis. These agents displayed a capacity to reduce inflammatory biomarkers
in phase II trials [29] however the STABILITY trial (Stabilisation of atherosclerotic plaque by initiation
of darapladib therapy) showed darapladib, another PLA2 inhibitor, failed to reduce cardiovascular
mortality, MI or stroke rates in patients with stable heart disease [30]. A different route being attempted
focuses on CRP and the cytokine pathways directly. Indeed, therapies targeting tumour necrosis factor
(TNF) and IL-6 are already routinely used as disease modifying anti-rheumatic drugs (DMARDs)
where they have been shown to protect against acute cardiovascular events [31]. Phase IV trials are
now underway to assess the cardioprotective role of these drugs [32].
Most recently, the phase III CANTOS study (Canakinumab ANti-inflammatory Thrombosis
Outcome Study) assessed the use of canakinumab (an IL-β targeted monoclonal antibody) in post-MI
patients who have a CRP >3 mg/L at the time of recruitment [33]. The results were mixed as whilst the
trial managed to significantly reduce cardiovascular events, it did not reduce overall mortality because
a reduction in cardiovascular mortality was offset by an increase in deaths due to infection. Finally,
given the key role of chemokines in atherosclerosis, chemokine targets might offer potential therapeutic
benefit in future. Certainly, in experimental work this approach has produced dramatic effects as
demonstrated by the plaque reductions in the ApoE−/− CCR2−/− and ApoE−/− CCR5−/− murine
models [34,35] or the anti-atherogenic effects of chemokine inhibitors in in-vivo murine models [36,37].
Whilst long term chemokine inhibition is undesirable, this approach could show efficacy in acute
secondary prevention in those with recent cardiovascular events who are noted to have ongoing
cardiovascular inflammation. Clinical trials of anti-inflammatory agents in atherosclerosis have been
summarised in Table 1.
Table 1. Notable clinical trials of anti-inflammatory agents in atherosclerosis. CRP: C-reactive protein;
PLA2: phospholipase 2; MI: myocardial infarction.
Trial Intervention Design Outcome
ARISE
Succinobucol in those with
previous acute coronary
syndrome
Double-blinded randomised
controlled trial (RCT) with
placebo as control; n = 6144
No significant clinical benefits
over placebo
JUPITER
Rosuvastatin in those
without hyperlipidaemia
but with elevated CRP
Double blinded RCT with
placebo as control; n = 17,802
Rosuvasatin significantly
reduced rates of stroke, MI or
cardiovascular death
STABILITY
Darapladib (PLA2 inhibitor)
in stable coronary heart
disease
Double blinded RCT with
placebo as control; n = 15,828
Darapladib did not significantly
affect rates of MI, stroke, or
cardiovascular death
CANTOS
Canakinumab (Il-1 inhibitor)
in those with previous MI
and raised baseline CRP
Double blinded RCT with
different dose groups and
placebo as control; n = 10,061
Canakinumab doses of 150 mg
or more reduced rates of MI but
not overall mortality
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3. Myocardial Infarction
3.1. The Use of Inflammatory Biomarkers in Myocardial Infarction
MI describes the death of cardiac tissue due to prolonged ischaemia (>20 min) through the
occlusion of a coronary vessel, usually by lumen-reducing atherosclerotic plaques and subsequent
thrombus formation [38]. It is one of the leading causes of death in the Western world with over
69,000 deaths in the United Kingdom in 2014 [39]. The inflammatory insult in MI is apparent and thus
inflammatory biomarkers have attracted more interest than that seen in subclinical atherosclerosis.
The degree of insult seen also suggests that even crude measurements of inflammation such as CRP
correlate to the underlying inflammation in the infarction [40]. Consequently, it is now well established
that the acute phase reactants hs-CRP, serum amyloid A (SAA) and pregnancy-associated plasma
protein (PAPP-A) all positively correlate with traditional cardiac biomarkers such as troponin I or
creatinine phosphokinase following acute MI [7,41]. Further to this, these inflammatory biomarkers
have all been shown to be able to strongly predict the future risk of coronary events, heart failure and
mortality after acute myocardial infarction [42]. Patients with elevated hs-CRP also seem to particularly
benefit from statins and anti-platelet agents following acute MI [23].
Similarly, IL-6 and TNFα have predictive value for mortality and future coronary events following
acute myocardial infarction [43]. In the FRISC-II trial (FRagmin and Fast Revascularisation during
InStability in Coronary artery disease), IL-6 was shown to predict mortality in those presenting with
mortality and those with elevated IL-6 were shown to exclusively have a mortality benefit from an
early invasive strategy whereas those with normal levels did not. More recently, studies have been
published that demonstrate correlation of macrophage migration inhibitory factor (MIF) with infarct
size and post-infarct left ventricular ejection fractions suggesting prognostic value with this biomarker
as well [44]. Beyond acute phase reactants, it has been shown that neutrophilia is a strong predictor
of mortality following acute MI [45]. There is also an expansion of the CD14++ CD16+ monocyte
population (previously discussed) after infarction [46] which has now also been shown to be able to
predict future risk of cardiac events [29]. Based on murine models, it is highly likely that this cell type
has a role in the inflammatory components of infarction resolution [16].
3.2. The Use of Anti-Inflammatory Therapies in Myocardial Infarction
The role of immune cells in scar formation and resolution in MI makes the development of
any anti-inflammatory therapies difficult. Such therapy would have to carefully modulate the
immune system to prevent excess inflammation whilst allowing wound healing. Nevertheless, several
therapies have been tried in this field. Some of the most potent anti-inflammatory agents available
are glucocorticoids and, despite concerns, they have been used in several clinical trials of patients
following acute MI. A recent meta-analysis demonstrated a 26% relative risk reduction in mortality
although this effect was not seen when analysis only included larger studies [47]. Conversely, there
was no excessive risk of rupture, easing concerns over poor wound healing. Nevertheless, steroids are
associated with volume retention, oedema and hyperglycaemia and so are currently not recommended
to be used in the management of acute MI [48]. Another widely used class of anti-inflammatory drugs
investigated in the context of acute MI are non-steroidal anti-inflammatory drugs (NSAIDs). However,
the evidence consistently shows worse clinical outcome with their use [49]. To refine this therapy, the
NUT-2 trial (Non-steroidal anti-inflammatory drugs in Unstable angina Treatment) utilised meloxicam,
a cyclo-oxygenase 2 (COX-2) selective inhibitor, which produced significant reductions in mortality
and further MI rates after 90 days [50]. Despite this promising early result, a 2006 meta-analysis
concluded that selective COX-2 inhibitors are associated with an increased risk of vascular events [51].
The complement cascade has also been investigated as a potential target given its early activation
following myocardial infarction and several agents have shown promising results in preclinical
studies. Pexelizumab, a monoclonal antibody against C5, demonstrated a significant decrease in
mortality in a phase II clinical trial [52] however the APEX-AMI study (Assessment of Pexelizumab
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in Acute Myocardial Infarction) failed to demonstrate any effect of the agent on mortality after acute
MI [53]. Finally, the cytokine system has also been targeted: IL-1 is a pro-inflammatory cytokine
and experimental models suggest Il-1 blockade to be beneficial in the context of MI [54]. Recently,
two phase II studies utilised anakinra (a recombinant IL-1 receptor agonist) in patients following
primary PCI and demonstrated reductions in CRP levels coupled with lower incidence of heart failure
at 3 months [55,56]. A larger phase II trial is due to publish its results in late 2018 [57]. Clinical trials of
anti-inflammatory agents in MI have been summarised in Table 2.
Table 2. Notable clinical trials and meta-analyses of anti-inflammatory agents in MI. ACS: acute
coronary syndrome; PCI: percutaneous coronary intervention.
Trial/Meta-Analysis Intervention Design Outcome
NUT-2
Meloxicam (COX2 inhibitor)
plus standard treatment in
ACS patients
Single blinded RCT with
standard treatment as control;
n = 120
Significant reduction in
recurrent MI and deaths with
meloxicam
APEX-AMI Pexelizumab (anti-C5) inpatients receiving PCI for MI
Double blinded RCT with
placebo as control; n = 5745
No significant differences
between treatment or placebo
FRISC-II
Early invasive strategy
post-MI for those with
significant risk factors
including IL-6/CRP levels
Risk stratification into
intervention or normal
treatment. Raised IL-6/CRP
levels as risk factors; n = 2457
Early invasive strategy in
these patients significantly
reduced rates of MI but not
mortality
Pooled results of
VCU-ART1 and
VCU-ART2
Anakinra (IL-1 antagonist) for
post MI patients
Double blinded RCTs with
placebo as control; combined
n = 70
Significant reduction in
developing heart failure post
MI with anakinra
Meta-analysis of
corticosteroid
treatment in MI
Glucocorticoids in post-MI
patients
Meta-analysis of 11 controlled
studies of glucocorticoids
versus placebo
No significant clinical benefits
with glucocorticoids
Meta-analysis of
COX-2 inhibitor use
COX-2 inhibitors in a variety
of patient populations
Met-analysis of 138 RCTs of
COX-2 inhibitors versus
placebo/NSAID/both
COX-2 inhibitors significantly
increase risk of MI
4. Reperfusion Strategies
Inflammation and Anti-Inflammatory Strategies in Reperfusion Techniques
In patients who have suffered with clinical atherosclerosis and MI, reperfusion is a frequently
used therapy [56]. In those identified to be benefit from reperfusion, there are two main treatment
modalities: CABG and PCI. In the United Kingdom alone there were 16,791 CABG operations and
92,445 PCI procedures in 2012 [44]. Both procedures are invasive, directly involve manipulation of the
coronary vasculature, and necessarily lead to reperfusion of ischaemic areas. Consequently, systemic
inflammation is seen following either procedure in the form of elevated cytokine levels [58,59].
This is particularly the case with CABG which not only has the systemic inflammatory response
associated with major surgery but the added inflammatory stimulus of cardio-pulmonary bypass
(CPB) in on-pump surgery. CPB now has a well-documented inflammatory response through a
variety of proposed mechanisms [60]. Indeed, it is plausible that a significant portion of the clear
benefits of off-pump surgery are due to a suppressed inflammatory response in this form of CABG [61].
The adverse outcomes associated with a marked inflammatory response following CABG, from
post-operative fever to profound organ dysfunction [60,61], have led to concerted attempts to suppress
the post-operative inflammatory response. For example, post-operative atrial fibrillation (the most
common major complication of CABG) has a well-defined positive correlation with IL-6 and CRP
levels post-operatively [62].
Several RCTs have focused on improving the extra-corporeal circuits and whilst they show clinical
benefit, it is not however consistently linked to a correlated reduction in inflammation [63]. There have
been multiple RCTs utilising corticosteroids, however a Cochrane review on corticosteroids in cardiac
surgery showed no benefit to morbidity or mortality [64]. Rosuvastatin has also been incorporated in a
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recent RCT (Statin Therapy In Cardiac Surgery) where it was administered perioperatively in elective
cardiac surgery [65]. Whilst it reduced CRP levels post-operatively, it did not reduce post-operative
AF or cardiac damage compared to placebo.
In addition, there have also been several pilot studies utilising a variety of anti-inflammatory
strategies in cardiac surgery including delivery of Nitrous Oxide [66] and neutrophil elastase
inhibitors [67]. Whilst they showed a reduction in inflammation, clinical outcomes were not measured.
In the case of PCI, whilst there is an inflammatory response, the correlation between the degree of
inflammation (as measured by typical cytokines) and adverse outcomes has only been reproducible in
studies with bare metal stents, not modern stents, although there are new promising biomarkers [68].
Nevertheless, restenosis following PCI is considered an inflammatory response to vascular injury as
are other post-PCI complications [69] and thus anti-inflammatory strategies have been attempted. The
stent is an obvious point for intervention and the superiority of drug eluting stents (DESs) is now
well established [70]. The agents most commonly used are selected for anti-proliferative qualities,
such as the rapamycin derivatives, though these agents also display anti-inflammatory activity [71]. A
novel agent is titanium–nitric oxide which works exclusively on an anti-oxidative/anti-inflammatory
basis [72]; it has so far proved comparable to several DESs. Finally, systemic anti-inflammatory therapy
has also been attempted in the form of corticosteroids: The IMPRESS trial (Efficacy of Intramuscular
Methyl-prednisone to prevent Restenosis after coronary artery stenting with bare-metal stainless steel
stents) demonstrated higher event-free survival following use of prednisone after PCI with bare metal
stents (BMS) for instance [73]. The four-year follow up in the CEREA-DES trial (Cortisone plus BMS or
DES versus BMS alone to eliminate restenosis) showed these positive effects were maintained and that
this combination is comparable to drug eluting stents [74]. Clinical trials of anti-inflammatory agents
in PCI/CABG have been summarised in Table 3.
Table 3. Notable clinical studies and meta-analyses of anti-inflammatory therapies in PCI/ coronary
artery bypass grafting (CABG).
Trial/Meta-Analysis Intervention Design Outcome
STICS Rosuvastatin in electivecardiac surgery
Double blinded RCT
with a placebo as control;
n = 1922
Rosuvastatin did reduce
CRP but did not significantly
affect post-operative
outcomes
CEREA-DES Prednisone with baremetal stents in PCI
Single blinded RCT with
drug eluting stents and
bare metal stents without
prednisone as other
treatments; n = 375
Bare metal stents with
prednisone and drug eluting
stents both have higher
event free survival
compared to bare metal
stents only
Meta-analysis of
corticosteroids in
cardiac surgery
High dose prophylactic
steroids administered in
on-pump CABG
54 RCTS included of
variable quality;
total n = 3615
No significant clinical
benefits with corticosteroids
5. Heart Failure
5.1. Inflammation in Heart Failure
One of the most serious consequences of atherosclerosis and MI, particularly in the absence or
failure of reperfusion, is the development of heart failure. Heart failure is defined as inadequate
cardiac function and affects 1–2% of the adult population. It is associated with a poor prognosis with
1-year mortality at 30–40% [44]. Since 1990, there has been a recognised contribution of inflammation
to heart failure following a study by Levine et al. which demonstrated elevated levels of TNF in heart
failure patients [75]. Subsequently, TNF has been demonstrated, in animal studies, to have profound
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negative inotropic effects whether that be via direct injection [76] or through cardiac-restricted gene
overexpression [77].
Long term animal studies have also been able to demonstrate the capacity of TNF to induce
deleterious left ventricular remodelling [78]. Indeed, experimental models have now linked several
aspects of the innate immune system to myocyte apoptosis, myocardial fibrosis, foetal cardiac gene
expression and myocardial matrix metalloproteinase activation [79]. Analogous to the neurohormonal
pathways implicated in heart failure, inflammation in heart failure appears to initially be an attempt to
restore homeostasis but in the absence of recovery chronically contributes to the disease process. It
is however difficult to modulate the immune system in heart failure in such a way as to enable
attempts to restore homeostasis whilst sparing the heart from the chronic deleterious effects of
uncontrolled inflammation.
5.2. The Use of Inflammatory Biomarkers in Heart Failure
There is a clear and established role for the use of inflammatory biomarkers in heart failure. CRP
has been shown to elevated in more severe grades of heart failure and can independently predict
morbidity and mortality in heart failure [80] and TNF levels have been shown to do the same [81].
Further to this, the Food and Drugs Administration (FDA) has recently approved two prognostic
inflammatory biomarkers in heart failure, these being soluble ST2 (a receptor for IL-33) and galectin-3 (a
lectin released by activated macrophages and damaged cells). There is now also interest in pentraxin-3
(a novel cytokine) as a biomarker in heart failure too [82].
In similarity to subclinical atherosclerosis and MI, there is now also an implicated role for the
CD14++ CD16+ monocyte population. Recently, this population was shown to be significantly increased
in patients with congestive heart failure and the level of this population correlates to the severity of
heart failure, left ventricular ejection fraction (LVEF) and pro-brain natriuretic peptide levels [83]. This
population may well be directly contributing to heart failure and the potential for it as an inflammatory
biomarker in this condition is clear.
5.3. The Use of Anti-Inflammatory Therapies in Heart Failure
With the apparent contribution of TNF to heart failure pathophysiology, it has emerged as a
distinct target in clinical trials. Pentoxifylline and thalidomide have both been shown to reduce
TNF production as well as other pro-inflammatory mediators and in several small clinical trials have
demonstrated a capacity to improve LVEF and symptoms in patients with heart failure [84,85] though
not mortality.
Further to this, etanercept has also been trialled in the RECOVER (Research into Etanercept
CytOkine Antagonism in VentriculaR dysfunction) and RENAISSANCE (Randomised Etanercept
North American Strategy to Study Antagonism of CytokinEs) studies (collectively analysed as the
Randomised EtaNErcept Worldwide evALuation) with a combined total of 1500 heart failure patients.
These studies, however, failed to show a benefit of etanercept on a variety of primary outcomes and the
RENAISSANCE trial specifically demonstrated a significant worsening of heart failure in patients [86].
Infliximab (a monoclonal antibody against TNF) was also trialled in the ATTACH study (Anti-TNF
Therapy Against Congestive Herat failure) and increased mortality and hospitalization rates at higher
doses [87].
Dexamethasone has also been trialled in idiopathic dilated cardiomyopathy patients with heart
failure and was able to demonstrate no significant benefits over placebo [88]. Statins have been the
subject of interest in heart failure as well. The CORONA [89] (Crestor versus placebo in subjects with
Heart Failure) and GISSI-HF [90] (Effect of rosuvastatin in patients with chronic heart failure) trials
were both large RCTs that sought to investigate the use of rosuvastatin as an intervention in heart
failure. Neither could demonstrate an effect of rosuvastatin on death or hospital admission due to
cardiovascular reasons. However, post hoc analysis of the CORONA trial did reveal benefits to patients
with baseline CRP levels >2 mg/dL in line with the results we saw in subclinical atherosclerosis [91].
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Finally, methotrexate has also been trialled in heart failure patients due to its ability to reduce
heart failure rates in patients with rheumatoid arthritis [35]. The METIS trial (Methotrexate therapy on
the physical capacity of patients with Ischaemic heart failure) was a small clinical trial that evaluated
methotrexate against a placebo in 50 heart failure patients, but it found no significant differences [92].
However, heart failure related outcomes following methotrexate treatment are being included in the
much larger CIRT study which should have greater power to detect benefits [93]. Clinical trials of
anti-inflammatory agents in heart failure have been summarised in Table 4.
Table 4. Notable clinical studies of anti-inflammatory therapies in heart failure patients.
Trial Intervention Design Outcome
RENEWAL Etanercept in heart failurepatients (NYHA II-IV)
Two double-blinded RCTs with
placebo as control; n = 2048
No significant clinical benefits of
etanercept over placebo
ATTACH Infliximab in heart failurepatients (NYHA III-IV)
Double-blinded RCT with
placebo as control; n = 150
No significant clinical benefits.
High dose infliximab increased
mortality
Prednisone in
Idiopathic Dilated
Cardiomyotpathy
Prednisone in patients with
idiopathic dilated
cardiomyopathy
Single-blinded RCT with
placebo as control; n = 102
No significant clinical benefits
with prednisone over placebo
CORONA Rosuvastatin in heart failurepatients (NYHA II-IV)
Double-blinded RCT with
placebo as control; n = 5011
Reduction in hospitalization
rates if patient has multiple
admissions or CRP >2
GISSI-HF Rosuvastatin in heart failurepatients (NYHA II-IV)
Double-blinded RCT with
placebo as control; n = 4574
No significant clinical benefits
with rosuvastatin over placebo
METIS
Methotrexate plus folic acid
in ischaemic heart failure
patients
Double-blinded RCT with
placebo and folic acid as control;
n = 50
No significant clinical benefits
with methotrexate over placebo
6. Conclusions
In conclusion, there is a prominent role for inflammation in several aspects of cardiovascular
medicine from atherosclerosis and one of its major consequences in MI. Inflammation is involved in
the reperfusion strategies used to address these conditions as well as heart failure, one of the major
consequences of MI and failed reperfusion.
This review demonstrates groups of patients who have a significant inflammatory component
contributing to their cardiovascular disease. These patients can often be detected with the use of
current inflammatory biomarkers with several more promising and robust biomarkers on the horizon.
This stratification has the potential to improve prognostic accuracy and identify distinct patient groups
who might benefit from anti-inflammatory strategies. There is evidence already that such strategies
are of benefit in cardiovascular medicine and there exists the potential to expand both the scope and
efficacy of such strategies.
In future, we will hopefully be able to identify ever more specific targets to the inflammatory
component of a patient’s cardiovascular disease which in turn will allow specifically tailored therapies
that may prove to be of benefit. This is in stark contrast to the blunt anti-inflammatory therapies
discussed in this review. With all of this in mind, the links between basic, translational and clinical
research will prove more important than ever. Indeed, this review already demonstrates how quickly
these therapeutics have gone from the bench side to clinic. If we are to have success, then the relevant
research scientists will need to closely follow these clinical trials in order to refine their hypotheses. In
turn, clinical scientists will need to keep abreast of developments in translational research in order to
identify and trial promising therapeutics sooner rather than later.
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